 James S. Hu, MD
|
| Title(s) | Clinical Associate Professor of Medicine (Clinician Educator) |
|---|
| Address | NOR 3440
Health Sciences Campus
Los Angeles CA 90089-9173
|
|---|
| Phone | +1 323 865 0813 |
|---|
| vCard | Download vCard |
|---|
|
|
 Biography | American College of Physicians | 2006 | | Fellow | | Keck School of Medicine | 2011 | | Oncology Fellowship Teacher of the Year | | 2013 | | Meritorious Service Medal |
Overview James Hu, MD, FACP, is the medical director of the Sarcoma Program of USC, and is considered one of the nation’s experts in the disease. Dr. Hu has more than 20 years of clinical experience in medical oncology and brings this acumen to the bedside. Understanding the rarity of sarcoma cancers, Dr. Hu has the breadth of clinical experience as well as the academic discipline to provide each patient with an individualized treatment program. He has collaborated with other national experts to bring clinical trials to USC. He is a member of the Connective Tissue Oncology Society, and has linked the Sarcoma Program of USC with the international collaborative group: Sarcoma Alliance for Research through Collaboration (SARC), to further direct research into sarcoma.
Dr Hu has authored several review articles on sarcoma, in both national and international peer reviewed journals. As a former military commander of a combat support hospital, Dr. Hu has years of experience in the issues surrounding young adult disease and along with Dr. Siegel, is the co-director of the Adolescent and Young Adult program of USC and Children’s Hospital Los Angeles. This program offers specialized services tailored to adolescent and young adult patients who comprise a significant portion of patients diagnosed with sarcomas. Dr Hu and his medical oncology team pride themselves on patient accessibility and are committed to providing comprehensive oncology care to the patient with sarcoma.
Dr. Hu is a local Angeleno, having grown up in the neighborhood surrounding LAC+USC Medical Center. Dr Hu is proud to be a part of USC and grateful for an opportunity to give back to his community.
ORNG Applications Bibliographic
Altmetrics Details
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media.
(Note that publications are often cited in additional ways that are not shown here.)
Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication.
Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication.
Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.)
Click a Field or Translation tag to filter the publications.
-
Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. Cancer. 2020 Nov 18.
Tseng WW, Barretta F, Conti L, Grignani G, Tolomeo F, Albertsmeier M, Angele MK, Rutkowski P, Skoczylas J, De Paoli A, Navarria F, Raut CP, Fairweather M, Farma JM, Nessim C, Goel N, Grignol VP, Ford SJ, Cardona K, Subhawong T, Tattersall HL, Lee RM, Hu JS, von Mehren M, Sanfilippo R, Gronchi A. PMID: 33206381.
View in: PubMed Mentions: Fields:
-
Circulating tumor cells and biomarker modulation with olaratumab monotherapy followed by olaratumab plus doxorubicin: phase 1b study in soft tissue sarcoma patients. Mol Cancer Ther. 2020 Nov 11.
Martín-Broto J, Lopez Pousa A, Brohl AS, Van Tine BA, Powers B, Stacchiotti S, Blay JY, Hu JS, Oakley GJ, Wang H, Szpurka AM, Levy DE, Mo G, Ceccarelli M, Jones RL. PMID: 33177152.
View in: PubMed Mentions: Fields:
-
Predictors of readmission after craniotomy for meningioma resection: a nationwide readmission database analysis. Acta Neurochir (Wien). 2020 11; 162(11):2637-2646.
Lin M, Min E, Orloff EA, Ding L, Youssef KSR, Hu JS, Giannotta SL, Mack WJ, Attenello FJ. PMID: 32779026.
View in: PubMed Mentions: Fields:
-
Staging systems and nomograms in soft tissue sarcoma: outcome prediction by categorization or personalization? Chin Clin Oncol. 2019 Oct; 8(S1):S12.
Tseng WW, Pasquali S, Hu JS, Menendez LR, Gronchi A. PMID: 30943728.
View in: PubMed Mentions: Fields: Translation: Humans
-
Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma. JAAD Case Rep. 2018 Nov; 4(10):1004-1006.
Lara KM, In GK, Matcuk GR, Mehta A, Hu JS. PMID: 30450405.
View in: PubMed Mentions:
-
Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer. 2017 Dec 01; 123(23):4566-4573.
Dorff TB, Longmate JA, Pal SK, Stadler WM, Fishman MN, Vaishampayan UN, Rao A, Pinksi JK, Hu JS, Quinn DI, Lara PN. PMID: 28832978.
View in: PubMed Mentions: 5 Fields: Translation: Humans
-
Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Aug; 9(8):533-550.
In GK, Hu JS, Tseng WW. PMID: 28794805.
View in: PubMed Mentions:
-
Contemporary Management of Retroperitoneal Soft Tissue Sarcomas. Curr Oncol Rep. 2015 Aug; 17(8):39.
Olimpiadi Y, Song S, Hu JS, Matcuk GR, Chopra S, Eisenberg BL, Sener SF, Tseng WW. PMID: 26092408.
View in: PubMed Mentions: 7 Fields: Translation: Humans
-
Contrast-Enhanced Sonography for Monitoring Neoadjuvant Chemotherapy in Soft Tissue Sarcomas. J Ultrasound Med. 2015 Aug; 34(8):1489-99.
Gulati M, Hu JS, Desai B, Hwang DH, Grant EG, Duddalwar VA. PMID: 26206837.
View in: PubMed Mentions: 1 Fields: Translation: Humans
-
Salvage chemotherapy for refractory germ cell tumors. Oncology (Williston Park). 2014 Jun; 28(6):498-500.
Dorff TB, Hu JS, Quinn DI. PMID: 25134324.
View in: PubMed Mentions: Fields: Translation: Humans
This graph shows the total number of publications by year. To see the data as text, click here.
This graph shows the total number of publications by year. To return to the graph, click here.
| Year | Publications |
|---|
| 2014 | 1 | | 2015 | 2 | | 2017 | 2 | | 2018 | 1 | | 2019 | 1 | | 2020 | 3 |
This graph shows the number and percent of publications by field.
Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications.
Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written.
To see the data as text, click here.
This graph shows the number and percent of publications by field.
Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications.
Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written.
To see the data as text, click here.
newest
oldest
line numbers
double spacing
all authors
publication IDs
|
Derived automatically from this person's publications.
_
People in Profiles who have published with this person.
_
People who share similar concepts with this person.
_
Search Department
_
|